397 reports of this reaction
4.5% of all DEXTROMETHORPHAN HYDROBROMIDE AND GUAIFENESIN reports
#3 most reported adverse reaction
DIZZINESS is the #3 most commonly reported adverse reaction for DEXTROMETHORPHAN HYDROBROMIDE AND GUAIFENESIN, manufactured by RB Health (US) LLC. There are 397 FDA adverse event reports linking DEXTROMETHORPHAN HYDROBROMIDE AND GUAIFENESIN to DIZZINESS. This represents approximately 4.5% of all 8,751 adverse event reports for this drug.
Patients taking DEXTROMETHORPHAN HYDROBROMIDE AND GUAIFENESIN who experience dizziness should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
DIZZINESS is moderately reported among DEXTROMETHORPHAN HYDROBROMIDE AND GUAIFENESIN users, representing a notable but not dominant share of adverse events.
In addition to dizziness, the following adverse reactions have been reported for DEXTROMETHORPHAN HYDROBROMIDE AND GUAIFENESIN:
The following drugs have also been linked to dizziness in FDA adverse event reports:
DIZZINESS has been reported as an adverse event in 397 FDA reports for DEXTROMETHORPHAN HYDROBROMIDE AND GUAIFENESIN. This does not prove causation, but indicates an association observed in post-market surveillance data.
DIZZINESS accounts for approximately 4.5% of all adverse event reports for DEXTROMETHORPHAN HYDROBROMIDE AND GUAIFENESIN, making it one of the most commonly reported side effect.
If you experience dizziness while taking DEXTROMETHORPHAN HYDROBROMIDE AND GUAIFENESIN, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.